Cost-utility of implantable tibial neuromodulation (Revi) versus conservative therapy for urgency urinary incontinence in adults: a US payer perspective.

A cost-utility analysis published in the Journal of Medical Economics evaluated an implantable tibial neuromodulation device (Revi) against conservative treatments for urgency urinary incontinence in adults from a US payer standpoint. The study modeled quality-adjusted outcomes and costs to assess whether the implantable approach offers economic value compared to non-surgical options. Physical therapists managing pelvic floor dysfunction may encounter patients considering such device-based alternatives to conservative care.

Read full article at PubMed / J Med Econ ↗

About this summary. The text above is a short summary written for this site. The original article is hosted by PubMed / J Med Econ at the link above; this site does not reproduce the full article. Verify against the source before relying on specific details.